Aigen Investment Management LP bought a new stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 49,344 shares of the company's stock, valued at approximately $508,000.
Other hedge funds also recently added to or reduced their stakes in the company. King Luther Capital Management Corp increased its holdings in shares of Haleon by 31.7% in the first quarter. King Luther Capital Management Corp now owns 25,113 shares of the company's stock valued at $258,000 after purchasing an additional 6,050 shares during the period. Entropy Technologies LP grew its holdings in Haleon by 111.3% during the first quarter. Entropy Technologies LP now owns 168,644 shares of the company's stock worth $1,735,000 after acquiring an additional 88,843 shares during the period. Deutsche Bank AG grew its holdings in Haleon by 267.8% during the first quarter. Deutsche Bank AG now owns 3,126 shares of the company's stock worth $32,000 after acquiring an additional 2,276 shares during the period. Headlands Technologies LLC acquired a new stake in Haleon during the first quarter worth about $220,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in Haleon by 28.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 342,213 shares of the company's stock worth $3,521,000 after acquiring an additional 76,469 shares during the period. 6.67% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on the company. Barclays restated an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. Morgan Stanley upgraded Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 target price on the stock in a research report on Friday, May 9th. Wall Street Zen downgraded Haleon from a "buy" rating to a "hold" rating in a research report on Saturday, July 12th. BNP Paribas Exane upgraded Haleon from a "neutral" rating to an "outperform" rating and set a $13.40 target price on the stock in a research report on Tuesday, May 27th. Finally, BNP Paribas upgraded Haleon to a "strong-buy" rating in a report on Tuesday, May 27th. Five equities research analysts have rated the stock with a hold rating, three have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $12.33.
Check Out Our Latest Research Report on Haleon
Haleon Stock Performance
HLN stock traded down $0.06 during midday trading on Friday, reaching $9.64. The company had a trading volume of 7,875,929 shares, compared to its average volume of 13,045,589. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48. The stock has a 50 day moving average price of $10.07 and a 200 day moving average price of $10.20. The firm has a market capitalization of $43.30 billion, a PE ratio of 24.72, a P/E/G ratio of 2.86 and a beta of 0.23. Haleon PLC Sponsored ADR has a fifty-two week low of $8.86 and a fifty-two week high of $11.42.
Haleon Increases Dividend
The business also recently declared a semi-annual dividend, which will be paid on Thursday, September 18th. Stockholders of record on Friday, August 15th will be paid a $0.0555 dividend. This represents a dividend yield of 190.0%. This is a boost from Haleon's previous semi-annual dividend of $0.05. The ex-dividend date of this dividend is Friday, August 15th. Haleon's dividend payout ratio (DPR) is currently 64.10%.
Haleon Company Profile
(
Free Report)
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Featured Articles

Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.